While advancements in cellular therapy have improved outcomes for patients with refractory leukemia, severe infections may hinder access. Granulocyte transfusions, in combination with anti-microbial therapy, may be a safe option to facilitate candidacy for chimeric antigen receptor T-cell therapy in patients with leukemia and prolonged immune-compromised status.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MPH.0000000000002111 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Longitudinal assessment of erythrogram parameters in response to granulocytapheresis frequency: A sex-based analysis.
Vox Sang
January 2025
Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Background And Objectives: Granulocyte transfusion supports patients with severe neutropenia. Maintaining a pool of eligible donors and optimizing donation frequency are essential for ensuring an adequate supply while safeguarding donor well-being. This study investigates the impact of donation frequency on erythrogram parameters, focusing on sex-specific differences.
View Article and Find Full Text PDFComparison of HiDAC Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome.
Eur J Haematol
December 2024
Department of Hematology, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam, the Netherlands.
Background: Relapsed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) are associated with a poor prognosis. It is unknown which re-induction therapy provides the highest chance of durable remission. Commonly used therapies are high dose cytarabine (HiDAC) and triple therapy consisting of fludarabine, cytarabine, and idarubicin combined with granulocyte colony-stimulating factor (FLAG-IDA).
View Article and Find Full Text PDFProlonging neutrophil room temperature storage with clinically-approved solutions: Implications for granulocyte transfusion.
J Leukoc Biol
December 2024
Infectious and Immune Diseases Division, CHU de Québec Research Center, Laval University, Québec, QC, Canada.
Introduction: Granulocyte concentrates (GC) are leukocyte preparations enriched in neutrophils that can potentially save neutropenic patients from life-threatening, antimicrobial-resistant infections. The main challenge of GC transfusions is preserving the viability and antimicrobial activity of neutrophils beyond 24 h to reduce the logistical burden on collection centers and increase the availability of this cell therapy. Thus, the aim of this study was to explore extending the ex vivo viability and antimicrobial activity of GC neutrophils up to 72 h with a unique combination of the clinically-approved additives Plasma-Lyte, SAGM, AS-3 and Alburex.
View Article and Find Full Text PDFExtrasinusoidal macrophages are a distinct subset of immunologically active dural macrophages.
Sci Immunol
December 2024
Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Although macrophages in the meningeal compartments of the central nervous system (CNS) have been comprehensively characterized under steady state, studying their contribution to physiological and pathological processes has been hindered by the lack of specific targeting tools in vivo. Recent findings have shown that the dural sinus and its adjacent lymphatic vessels act as a neuroimmune interface. However, the cellular and functional heterogeneity of extrasinusoidal dural macrophages outside this immune hub is not fully understood.
View Article and Find Full Text PDFPurified Granulocyte Concentrates from Buffy Coats with Extended Storage Time.
Transfus Med Hemother
December 2024
Artcline GmbH, Rostock, Germany.
Article Synopsis
- Granulocyte concentrates (GCs) can be made from pooled buffy coats of whole blood donations, allowing for better availability and longer storage times compared to those made from single-donor apheresis, which can only last 24 hours.
- A process was developed to significantly reduce red blood cell and platelet contamination, extending the shelf life of GCs up to 72 hours while maintaining high cell viability (above 98%) and functionality (with over 95% rates of phagocytosis and oxidative burst).
- To produce a therapeutic dose of GCs, around 15-20 buffy coats are needed, offering a more efficient alternative for treatment compared to traditional methods.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!